PTCB Supply Chain And Inventory Management Practice Test

Market potential forecasts are not part of an NDA submission because the regulatory review focuses on safety, efficacy, and product quality, along with information that affects labeling and patent status. The FDA needs proposed labeling to ensure the approved use, dosing, warnings, and adverse events are clearly communicated. Safety updates are included to provide the latest data on risks and benefits, which can influence labeling and the overall risk–benefit assessment. Patent information is also included to disclose the status of patents and exclusivity that can affect market protection and regulatory timing. In short, the NDA package centers on safety, efficacy, labeling, manufacturing, and patent/exclusivity considerations; market potential forecasts fall outside this regulatory scope.